{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:15:31Z","timestamp":1793369731604,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.04.108","type":"journal-article","created":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T02:52:02Z","timestamp":1354243922000},"page":"F123-F138","source":"Crossref","is-referenced-by-count":665,"special_numbering":"S5","title":["A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines"],"prefix":"10.1016","volume":"30","author":[{"given":"John T.","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Castellsagu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.04.108_bib0005","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26S","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"issue":"S5","key":"10.1016\/j.vaccine.2012.04.108_bib0445","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction \u2013 The first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2012.04.108_bib0015","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2012.04.108_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV - immune response to infection and vaccination","volume":"5","author":"Stanley","year":"2010","journal-title":"Infect Agent Cancer"},{"issue":"S5","key":"10.1016\/j.vaccine.2012.04.108_bib0450","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines \u2013 Immune responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2012.04.108_bib0030","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.vaccine.2012.04.108_bib0035","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"issue":"S5","key":"10.1016\/j.vaccine.2012.04.108_bib0455","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of HPV and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2012.04.108_bib0050","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.vaccine.2006.05.119","article-title":"Chapter 11: HPV vaccines: Commercial Research & Development","volume":"24","author":"Inglis","year":"2006","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","article-title":"GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14712598.2011.573624","article-title":"Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile","volume":"11","author":"Garcon","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"31","key":"10.1016\/j.vaccine.2012.04.108_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/oxfordjournals.jncimonographs.a003472","article-title":"Chapter 16: Prophylactic human papillomavirus vaccines","author":"Lowy","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"19","key":"10.1016\/j.vaccine.2012.04.108_bib0070","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.04.108_bib0075","doi-asserted-by":"crossref","unstructured":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 May 10;356(19):1915-27.","DOI":"10.1056\/NEJMoa061741"},{"issue":"9580","key":"10.1016\/j.vaccine.2012.04.108_bib0080","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"37","key":"10.1016\/j.vaccine.2012.04.108_bib0085","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"issue":"9590","key":"10.1016\/j.vaccine.2012.04.108_bib0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.04.108_bib0100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res (Phila)"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.vaccine.2012.04.108_bib0110","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.04.108_bib0125","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.vaccine.2011.01.001","article-title":"HPV16\/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection","volume":"29","author":"Kemp","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discovery"},{"issue":"19","key":"10.1016\/j.vaccine.2012.04.108_bib0135","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.vaccine.2012.04.108_bib0140","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.04.108_bib0145","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9706","key":"10.1016\/j.vaccine.2012.04.108_bib0155","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ijc.26362","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16\/18","volume":"131","author":"Szarewski","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.04.108_bib0165","doi-asserted-by":"crossref","unstructured":"Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007 Nov 15;196(10):1438-46.","DOI":"10.1086\/522864"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.vaccine.2012.04.108_bib0175","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"issue":"21","key":"10.1016\/j.vaccine.2012.04.108_bib0180","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.vaccine.2012.04.108_bib0185","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0190","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4161\/hv.5.5.7211","article-title":"Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials","volume":"5","author":"Descamps","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.04.108_bib0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-11-13","article-title":"Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2012.04.108_bib0200","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.04.108_bib0205","doi-asserted-by":"crossref","first-page":"c712","DOI":"10.1136\/bmj.c712","article-title":"Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials","volume":"340","author":"Wacholder","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0210","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0215","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6\/11\/16\/18 vaccine","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.vaccine.2012.04.108_bib0220","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0225","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsague","year":"2011","journal-title":"Br J Cancer"},{"issue":"9679","key":"10.1016\/j.vaccine.2012.04.108_bib0235","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2012.04.108_bib0240","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"issue":"2 Suppl","key":"10.1016\/j.vaccine.2012.04.108_bib0245","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ygyno.2008.02.002","article-title":"Age considerations when vaccinating against HPV","volume":"109","author":"Wright","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.04.108_bib0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/infdis\/jir281","article-title":"Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses","volume":"204","author":"Westra","year":"2011","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2012.04.108_bib0260","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"10.1016\/j.vaccine.2012.04.108_bib0265","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ygyno.2010.04.003","article-title":"Measuring serum antibody to human papillomavirus following infection or vaccination","volume":"118","author":"Frazer","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0280","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4161\/hv.4.2.5261","article-title":"Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11","volume":"4","author":"Smith","year":"2008","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0285","doi-asserted-by":"crossref","DOI":"10.4161\/hv.7.2.13948","article-title":"The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay","volume":"7","author":"Brown","year":"2011","journal-title":"Hum Vaccin"},{"issue":"10","key":"10.1016\/j.vaccine.2012.04.108_bib0290","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1128\/JVI.80.10.4664-4672.2006","article-title":"Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera","volume":"80","author":"Carter","year":"2006","journal-title":"J Virol"},{"issue":"12.","key":"10.1016\/j.vaccine.2012.04.108_bib0295","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: Follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"issue":"52","key":"10.1016\/j.vaccine.2012.04.108_bib0300","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2012.04.108_bib0305","doi-asserted-by":"crossref","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"26","key":"10.1016\/j.vaccine.2012.04.108_bib0310","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2012.04.108_bib0315","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.04.108_bib0320","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparison of the immunogenicity of the human papillomavirus (HPV)-16\/18 vaccine and the HPV-6\/11\/16\/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum Vaccin"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0325","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0330","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J Adolesc Health"},{"issue":"3","key":"10.1016\/j.vaccine.2012.04.108_bib0340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1128\/CVI.00489-10","article-title":"Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial","volume":"18","author":"Krajden","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2012.04.108_bib0345","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.vaccine.2012.04.108_bib0355","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0360","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.vaccine.2007.11.043","article-title":"Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6\/11\/16\/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines","volume":"26","author":"Wheeler","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2012.04.108_bib0365","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/INF.0b013e3181c177fb","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0370","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1542\/peds.2009-2336","article-title":"Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel","volume":"125","author":"Reisinger","year":"2010","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2012.04.108_bib0375","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jadohealth.2009.11.205","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women","volume":"46","author":"Garcia-Sicilia","year":"2010","journal-title":"J Adolesc Health"},{"issue":"5","key":"10.1016\/j.vaccine.2012.04.108_bib0380","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jnci\/djr053","article-title":"For cancers caused by HPV, two vaccines were just the beginning","volume":"103","author":"Peres","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.vaccine.2012.04.108_bib0385","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1006\/jmbi.2000.4464","article-title":"Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1","volume":"307","author":"Chen","year":"2001","journal-title":"J Mol Biol"},{"issue":"17","key":"10.1016\/j.vaccine.2012.04.108_bib0390","doi-asserted-by":"crossref","first-page":"7848","DOI":"10.1128\/JVI.75.17.7848-7853.2001","article-title":"Immunization with a pentameric L1 fusion protein protects against papillomavirus infection","volume":"75","author":"Yuan","year":"2001","journal-title":"J Virol"},{"issue":"43","key":"10.1016\/j.vaccine.2012.04.108_bib0395","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1016\/j.vaccine.2011.07.071","article-title":"Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles","volume":"29","author":"Hanumantha Rao","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2012.04.108_bib0400","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4161\/hv.7.3.14263","article-title":"Vaccine farming in Cape Town","volume":"7","author":"Rybicki","year":"2011","journal-title":"Hum Vaccin"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2012.04.108_bib0405","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2009.01.061","article-title":"Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma","volume":"27","author":"Cantarella","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2012.04.108_bib0410","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/JVI.80.6.2621-2630.2006","article-title":"Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1","volume":"80","author":"Kuck","year":"2006","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2012.04.108_bib0415","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00164-07","article-title":"Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever","volume":"14","author":"Fraillery","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2012.04.108_bib0420","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/icb.2009.13","article-title":"Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection","volume":"87","author":"Karanam","year":"2009","journal-title":"Immunol Cell Biol"},{"issue":"19","key":"10.1016\/j.vaccine.2012.04.108_bib0425","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of humoral immunity to common viral and vaccine antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.vaccine.2012.04.108_bib0430","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2010.04.070","article-title":"A summary of the post-licensure surveillance initiatives for GARDASIL\/SILGARD","volume":"28","author":"Bonanni","year":"2010","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2012.04.108_bib0435","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2012.04.108_bib0440","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1940-6207.CAPR-11-0284","article-title":"Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal \u201cpap-test equivalent\u201d in high-risk populations","volume":"4","author":"Fakhry","year":"2011","journal-title":"Cancer Prev Res (Phila)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:31:26Z","timestamp":1643740286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12009516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":88,"alternative-id":["S0264410X12009516"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.04.108","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}